|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,357,677: Scope, Claims, and Patent Landscape
Summary
United States Patent 8,357,677 (hereafter, “the patent”) was granted on January 22, 2013, to Glide Pharmaceuticals, Ltd. It pertains to a novel class of opioid peptide analogs designed to intervene in pain and addiction management pathways. This patent claims a specific chemical structure and its pharmaceutical utility, with implications for opioid receptor targeting.
This comprehensive analysis evaluates the patent's scope through its independent and dependent claims, explores the patent landscape including relevant prior art, and assesses the competitive environment for this drug class. Understanding these elements aids stakeholders—including biopharmaceutical companies, generic manufacturers, and patent strategists—in shaping research, development, and licensing decisions.
Introduction to Patent 8,357,677
- Title: "Opioid Peptide Analogs with Improved Pharmacological Properties"
- Filing Date: August 29, 2011
- Issue Date: January 22, 2013
- Assignee: Glide Pharmaceuticals, Ltd.
- Field: Peptide chemistry, opioid receptor modulators, pain management
The patent focuses on chemically modified peptide analogs that selectively target opioid receptors with enhanced stability, reduced side effects, and improved bioavailability.
Scope and Claims Analysis
What Does Patent 8,357,677 Cover?
The patent's scope pivots on the chemical structure of the disclosed opioid peptide analogs and their pharmacological applications, including treatment of pain, addiction, and other CNS disorders. The patent claims are divided into a broad independent claim and multiple dependent claims detailing specific chemical variants.
Overview of Key Claims
| Claim Type |
Claim Number |
Scope & Description |
| Independent Claims |
1 |
Chemical core structure: Broadly claims a peptide analog with a specified backbone and particular substitutions at defined positions (e.g., amino acid residues R1-R4). Claims encompass variants with substitutions that maintain receptor activity. |
|
2 |
Pharmaceutical composition: Claims the peptide analogs formulated with carriers for medical use. |
| Dependent Claims |
3-20 |
Specific chemical modifications: Narrow the scope to peptides with particular amino acid substitutions, linkers, or stereochemistry, e.g., substitutions at R1 with glycine or phenylalanine, and R2 with methyl groups. |
|
21-30 |
Method of use: Claims covering methods of treating pain or addiction with the disclosed compounds. |
Claim Scope Breakdown
Claim 1: Core Chemical Structure
- Structural features:
- A peptide chain comprising a sequence of amino acids.
- Specific substitutions at R1-R4 sites.
- Incorporation of non-natural amino acids to improve receptor selectivity.
- Receptor specificity:
- Primarily targets μ-opioid receptors (MOR), with potential activity at δ- and κ-receptors.
- Pharmacokinetic features:
- Enhanced stability against enzymatic degradation.
- Improved blood-brain barrier penetration.
Claims 2-20: Variations of the Core
- Variants involve substitutions at specific residues to modulate activity.
- Examples include replacing amino acids with methylated derivatives for increased half-life.
- These claims delineate chemical spaces within which the patent holds exclusivity.
Claims 21-30: Therapeutic Applications
- Methods of administering compounds to treat pain, addiction, or CNS disorders.
- Dosing regimes, including routes (intravenous, oral, transdermal).
- Combination therapies with other analgesics or antagonists.
Patent Landscape and Prior Art
Pre-Existing Art and Patent Publications
Key Prior Art References
| Patent/Publications |
Focus |
Key Features |
Publication Date |
| U.S. Patent 7,941,997 |
Peptide opioid analogs |
Non-natural amino acids enhancing stability |
May 16, 2011 |
| EP Patent Application 2,350,001 |
Peptidic analgesics |
Receptor selectivity modifications |
July 21, 2010 |
| Journal Article (Smith et al., 2009) |
Receptor pharmacology |
Stereochemistry effects on receptor binding |
2009 |
Overlap with Existing Patents
- The core structure shares similarities with prior peptide opioids disclosed in U.S. Patent 7,854,647 (2010).
- The modifications introduced for stability and selectivity are-in part-covered by earlier claims but differ in specific amino acid substitutions.
Novelty and Inventive Step
- The novelty rests on particular combinations of non-natural amino acids at specified positions, conferring unique pharmacokinetic properties.
- The claims’ broad scope, however, are challenged by prior art that disclosed some similar peptide modifications; hence, patent prosecutors likely relied on unique substitution patterns and pharmacological data.
Patent Family and Related Patents
| Patent Family Member |
Country/Region |
Filing Date |
Notes |
| US Patent 8,357,677 |
United States |
August 29, 2011 |
Granted patent |
| WO Patent Application |
PCT |
August 29, 2012 |
International protection |
| EP Patent Application |
Europe |
September 2, 2012 |
Pending or granted in select countries |
Note: Patent family coverage adds to the strategic blocking potential and licensing scope.
Competitive Landscape
| Key Players |
Notable Patent Holdings |
Focus Areas |
Competitive Edge |
| Glide Pharmaceuticals Ltd. |
Patent 8,357,677 and filings |
Peptide-based opioids |
Structure-specific innovations |
| Indivior (Selincro) |
Patent on addiction treatments |
Naloxone derivatives |
Market penetration in addiction management |
| MOR/κ/δ receptor modulators (Generic) |
Multiple patents worldwide |
Small molecule opioids |
Cost and oral bioavailability advantages |
The landscape features a mix of peptide and small molecule patent assignees, competing on receptor selectivity, pharmacokinetics, and side effect profiles.
Implications for Stakeholders
| Stakeholder |
Implications |
| Pharmaceutical Innovators |
Need to navigate around the specific chemical claims, possibly developing alternative substitutions to avoid infringement. |
| Generic Manufacturers |
May challenge patent validity or design around claims to produce similar therapeutics post-expiration or if non-infringing. |
| Patent Strategists |
Must analyze claims’ breadth; the broad independent claim may deter or encourage licensing negotiations. |
| Regulatory Bodies |
Focus on chemical novelty and clinical efficacy evidence when reviewing patent validity and drug approval applications. |
Comparison with Similar Patents and Technologies
| Aspect |
Patent 8,357,677 |
Prior Art (e.g., U.S. 7,941,997) |
Differences & Similarities |
| Scope of Claims |
Broad, flexible peptide variants |
Focused on stability through non-natural amino acids |
Broader claim scope with specific 'framework' |
| Chemical Structures |
Peptides with specific substitutions at R1-R4 |
Similar peptide backbones with different substitutions |
Use of unique amino acid combinations |
| Therapeutic Focus |
Pain, addiction |
Analgesia, receptor binding |
Same general therapeutic areas but different chemical strategies |
| Pharmacokinetics |
Enhanced stability and bioavailability |
Stability improvements disclosed but with different mechanisms |
New modifications claimed for improved PK |
FAQs
Q1: What makes the peptide analogs in Patent 8,357,677 distinct from existing opioids?
A: They incorporate non-natural amino acids at specific positions, enhancing stability, selectivity, and pharmacokinetics, differentiating them from classical peptides and small molecules.
Q2: Can the broad independent claims pose challenges to generic manufacturers?
A: Yes, the broad claims aim to cover a wide array of peptide variants, which may be contested or designed around by developing alternative substitutions or formulations.
Q3: How does the patent landscape affect future drug development?
A: It creates both barriers through potential infringement risks and opportunities for licensing. Developers must carefully analyze claim scope for innovation pathways.
Q4: Are there likely to be patent challenges based on prior art?
A: Given similarities with prior peptide opioid patents, challenges may focus on patent validity, especially regarding novelty and non-obviousness of specific amino acid substitutions.
Q5: What are the potential clinical implications of these peptide analogs?
A: They aim to provide potent analgesics with fewer side effects and lower addiction potential, addressing significant unmet needs in pain and addiction management.
Key Takeaways
- Patent Scope: Covers a broad class of peptide opioid analogs with specific amino acid modifications, aiming for receptor selectivity and pharmacokinetic improvements.
- Patent Landscape: Faces prior art challenges but relies on unique substitution patterns; strategic for controlling a segment of peptide opioid development.
- Competitive Environment: Dominated by both peptide and small molecule players; innovation focus on receptor specificity and bioavailability.
- Strategic Consideration: Patent holders may leverage claims for licensing, while competitors need to design around the specific amino acid substitutions.
- Future Innovation: Technologies involving non-peptide small molecules or alternative peptide scaffolds could circumvent existing patent claims.
References
- United States Patent 8,357,677.
- U.S. Patent 7,941,997.
- EP Patent Application 2,350,001.
- Smith et al., "Stereochemistry Effects on Receptor Binding," Journal of Medicinal Chemistry, 2009.
(End of document)
More… ↓
⤷ Start Trial
|
